Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44).
B. Gerber
Honoraria - AstraZeneca; GlaxoSmithKline; Novartis; Roche; Sanofi
Research Funding - Novartis
H. Eidtmann
Consultant or Advisory Role - Amgen; Novartis; Roche
M. Rezai
No relevant relationships to disclose
P. A. Fasching
Honoraria - Amgen; Novartis; Pfizer
H. Tesch
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Roche; Sanofi
Honoraria - GlaxoSmithKline; Novartis; Roche; Sanofi
H. Eggemann
No relevant relationships to disclose
I. Schrader
No relevant relationships to disclose
K. Kittel
No relevant relationships to disclose
C. A. Hanusch
No relevant relationships to disclose
R. Kreienberg
Consultant or Advisory Role - AstraZeneca; Novartis
Honoraria - Amgen; Cephalon; GlaxoSmithKline
C. Solbach
No relevant relationships to disclose
C. Jackisch
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Roche
G. Kunz
No relevant relationships to disclose
J. U. Blohmer
No relevant relationships to disclose
J. B. Huober
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Sanofi
M. Hauschild
No relevant relationships to disclose
S. Loibl
Consultant or Advisory Role - Roche
Honoraria - Roche
V. Nekljudova
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose
G. Von Minckwitz
Consultant or Advisory Role - Roche; Sanofi
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi